
Join to view full profile
222 E 41st St# W-LL300New York, NY 10017
Phone+1 646-825-6300
Fax+1 718-939-1167
Dr. Wysock is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. James Wysock is a urologist based in NY, NY.
He completed his medical education at Northwestern University's Feinberg School of Medicine in 2005, followed by surgical and urology residencies at New York Presbyterian Hospital (Cornell Campus) until 2011.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Urology, 2007 - 2011
New York Presbyterian Hospital (Cornell Campus)Residency, Surgery, 2005 - 2007
Northwestern University The Feinberg School of MedicineClass of 2005
Certifications & Licensure
NJ State Medical License 2023 - 2027
NY State Medical License 2007 - 2027
American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- ClariCore System Used in Transperineal Prostate Biopsy Start of enrollment: 2018 Oct 10
Publications & Presentations
PubMed
- Detection rate of PSMA PET MRI (18 F-Flotufolastat) at the onset of biochemical recurrence following radical prostatectomy.Herbert Lepor, Hebert Alberto Vargas, Majlinda Tafa, James S Wysock, Wei Phin Tan
EJNMMI Reports. 2026-10-09 - Water Vapor Therapy for the Management of Prostate Cancer: The VAPOR 2 Study Initial Results of Ablative Efficacy and Toxicity.Arvin George, Eric Giesler, Brian Mazzarella, Richard Levin, Daniel Frendl
The Journal of Urology. 2026-10-01 - Focal Cryo-ablation for Treatment of Intermediate Favorable Risk (Grade Group 2) Prostate Cancer.Herbert Lepor, Jared Fiske, Majlinda Tafa, Elizabeth Pirraglia, James S Wysock
Urology. 2026-08-01
Authored Content
- 6 Things Every Man Should Know About Penile Cancer, According to a UrologistNovember 2018
Press Mentions
Microplastics Discovered in Prostate TumorsFebruary 23rd, 2026
Intense Monitoring Makes Partial Gland Removal a Good Option for Many Prostate Cancer PatientsMarch 6th, 2025
Focal Therapy Society and Society of Urologic Robotic Surgeons September 19–21, 2024 Washington, DCDecember 12th, 2024
Professional Memberships
- Member
External Links
- NYU Urologyhttp://www.med.nyu.edu/urology/frontpage
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: